Reuters logo
BRIEF-Summit awarded BARDA contract worth up to $62 million
September 11, 2017 / 11:23 AM / 3 months ago

BRIEF-Summit awarded BARDA contract worth up to $62 million

Sept 11 (Reuters) - Summit Therapeutics Plc

* Summit awarded BARDA contract worth up to $62 million to support the development of ridinilazole for the treatment of C. difficile infection

* Summit Therapeutics Plc - on track to initiate two Phase 3 clinical trials of ridinilazole for CDI in first half of 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below